News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,773 Results
Type
Article (8162)
Company Profile (140)
Press Release (476374)
Multimedia
Podcasts (8)
Webinars (6)
Section
Business (166821)
Career Advice (305)
Deals (25755)
Drug Delivery (8)
Drug Development (52967)
Employer Resources (14)
FDA (9766)
Job Trends (8585)
News (238351)
Policy (17908)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (485)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33163)
ALS (104)
Alzheimer's disease (974)
Antibody-drug conjugate (ADC) (262)
Approvals (10374)
Artificial intelligence (327)
ASCO (161)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6968)
BIO (36)
BIOSECURE Act (1)
Biosimilars (109)
BioSpace Insights (20)
Biotechnology (88)
Bladder cancer (139)
Brain cancer (28)
Breast cancer (508)
Cancer (3644)
Cardiovascular disease (217)
Career advice (246)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (476)
Cervical cancer (34)
Clinical research (47912)
Collaboration (1240)
Commercialization (3)
Compensation (1447)
Complete response letters (34)
COVID-19 (760)
CRISPR (63)
C-suite (738)
Cystic fibrosis (85)
Data (5626)
Denatured (7)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4179)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (155)
Drug pricing (8)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73676)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87617)
Executive appointments (697)
FDA (12374)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (912)
Gene editing (125)
Generative AI (10)
Gene therapy (316)
GLP-1 (290)
Government (946)
Grass and pollen (2)
Guidances (281)
Healthcare (9317)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (57)
Indications (156)
Infectious disease (948)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (41)
IPO (12392)
IRA (2)
Job creations (1972)
Job search strategy (236)
JPM (1)
Kidney cancer (20)
Layoffs (61)
Legal (5196)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (508)
Lymphoma (250)
Machine learning (27)
Management (3)
Manufacturing (527)
Marketing (8)
MASH (118)
Medical device (8650)
Medtech (8790)
Mergers & acquisitions (14391)
Metabolic disorders (704)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (221)
Neuropsychiatric disorders (38)
Neuroscience (1819)
NextGen: Class of 2026 (3152)
Non-profit (842)
Obesity (223)
Opinion (16)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (472)
Patient recruitment (502)
Peanut (31)
People (41247)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15484)
Phase 2 (21401)
Phase 3 (14438)
Pipeline (7222)
Policy (18)
Postmarket research (1570)
Preclinical (6545)
Press Release (34)
Prostate cancer (191)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3022)
Recruiting (6)
Regulatory (14802)
Reports (19)
Research institute (582)
Resumes & cover letters (45)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (122)
Service/supplier (5)
Sickle cell disease (62)
Special edition (1)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
The Weekly (1)
Vaccines (318)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (102)
Last 7 days (435)
Last 30 days (1677)
Last 365 days (19119)
2026 (12050)
2025 (19271)
2024 (23008)
2023 (26570)
2022 (34616)
2021 (37190)
2020 (33494)
2019 (23267)
2018 (17485)
2017 (18802)
2016 (17941)
2015 (24273)
2014 (21680)
2013 (18136)
2012 (20223)
2011 (20445)
2010 (20333)
Location
Africa (231)
Alabama (73)
Alaska (2)
Arizona (300)
Arkansas (11)
Asia (17893)
Australia (2102)
California (11904)
Canada (3123)
China (517)
Colorado (480)
Connecticut (407)
Delaware (207)
Europe (24703)
Florida (1780)
Georgia (374)
Hawaii (3)
Idaho (46)
Illinois (695)
India (48)
Indiana (314)
Iowa (14)
Japan (398)
Kansas (101)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1193)
Massachusetts (7824)
Michigan (307)
Minnesota (559)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2608)
New Mexico (12)
New York (2806)
North Carolina (1267)
North Dakota (4)
Northern California (5959)
Ohio (276)
Oklahoma (14)
Oregon (16)
Pennsylvania (2244)
Puerto Rico (20)
Rhode Island (30)
South America (409)
South Carolina (76)
South Dakota (1)
Southern California (4945)
Tennessee (119)
Texas (1920)
United States (38655)
Utah (357)
Vermont (1)
Virginia (152)
Washington D.C. (38)
Washington State (920)
West Virginia (1)
Wisconsin (73)
484,773 Results for "exelixis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 5, 2026
·
20 min read
Press Releases
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
July 23, 2026
·
1 min read
Press Releases
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June 2026
May 28, 2026
·
1 min read
Press Releases
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May 2026
May 8, 2026
·
1 min read
Press Releases
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
·
20 min read
Press Releases
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
May 22, 2026
·
17 min read
Press Releases
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
April 22, 2026
·
1 min read
Press Releases
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
May 19, 2026
·
7 min read
Press Releases
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
June 22, 2026
·
7 min read
Cancer
Exelixis’ Kinase Blocker Sets ‘New Survival Bar’ in Third-Line Colorectal Cancer, Opening Road to FDA
With data from the Phase III STELLAR-303 study in the books, Exelixis is plotting a 2025 regulatory application for zanzalintinib.
October 21, 2025
·
2 min read
·
Tristan Manalac
1 of 48,478
Next
